Fiscal year 2024 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses VERV in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named VERV in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Sekar Kathiresan | $639,231 | $0 | $1,683,000 | $4,727,372 | $378,972 | $0 | $14,088 | $7,442,663 |
| Chief Executive Officer | ||||||||
| Andrew Bellinger | 243,846 | 0 | 573,750 | 2,038,946 | 0 | 0 | 574,358 | 3,430,900 |
| Former Chief Scientific Officer | ||||||||
| Allison Dorval | 469,423 | 0 | 573,750 | 1,617,732 | 206,712 | 0 | 14,088 | 2,881,705 |
| Chief Financial Officer | ||||||||
| Andrew Ashe | 389,077 | 0 | 459,000 | 1,348,110 | 172,260 | 0 | 11,618 | 2,380,065 |
| President, Chief Operating Officer and General Counsel | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Sekar Kathiresan | $7,442,663 | — | — | — |
| Andrew Bellinger | 3,430,900 | — | — | — |
| Allison Dorval | 2,881,705 | — | — | — |
| Andrew Ashe | 2,380,065 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Andrew Ashe | OPTION | — | — | — | — | — | $1,348,110 |
| Allison Dorval | OPTION | — | — | — | — | — | 1,617,732 |
| Andrew Ashe | PSU | — | — | — | — | — | 459,000 |
| Andrew Bellinger | OPTION | — | — | — | — | — | 2,038,946 |
| Allison Dorval | PSU | — | — | — | — | — | 573,750 |
| Andrew Bellinger | PSU | — | — | — | — | — | 573,750 |
| Sekar Kathiresan | PSU | — | — | — | — | — | 1,683,000 |
| Sekar Kathiresan | OPTION | — | — | — | — | — | 4,727,372 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Andrew Ashe | $0 | $459,000 | $1,348,110 | 25.4% |
| Allison Dorval | 0 | 573,750 | 1,617,732 | 26.2% |
| Andrew Bellinger | 0 | 573,750 | 2,038,946 | 22.0% |
| Sekar Kathiresan | 0 | 1,683,000 | 4,727,372 | 26.3% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Allison Dorval | RSU | 1,875 | — | $10,575 |
| Andrew Ashe | Option | 99,015 | 21.76 | — |
| Andrew Ashe | Option | 150,000 | 12.75 | — |
| Allison Dorval | Option | 30,943 | 33.25 | — |
| Allison Dorval | Option | 17,500 | 30.94 | — |
| Andrew Ashe | Option | 0 | 1.48 | — |
| Sekar Kathiresan | Option | 0 | 1.39 | — |
| Sekar Kathiresan | Option | 0 | 1.48 | — |
| Sekar Kathiresan | Option | 0 | 8.24 | — |
| Sekar Kathiresan | Option | 0 | 19 | — |
| Sekar Kathiresan | Option | 0 | 21.76 | — |
| Andrew Ashe | Option | 0 | 2.87 | — |
| Sekar Kathiresan | Option | 18,000 | 8.24 | — |
| Sekar Kathiresan | Option | 6,750 | 19 | — |
| Sekar Kathiresan | Option | 96,838 | 30.94 | — |
| Sekar Kathiresan | Option | 298,014 | 21.76 | — |
| Sekar Kathiresan | Option | 526,000 | 12.75 | — |
| Andrew Ashe | Option | 4,500 | 8.24 | — |
| Andrew Ashe | Option | 2,700 | 19 | — |
| Andrew Ashe | Option | 36,459 | 30.94 | — |
| Allison Dorval | Option | 180,000 | 12.75 | — |
| Sekar Kathiresan | Option | 0 | 2.87 | — |
| Sekar Kathiresan | Option | 0 | 34.88 | — |
| Sekar Kathiresan | RSU | 132,000 | — | 744,480 |
| Andrew Ashe | RSU | 36,000 | — | 203,040 |
| Sekar Kathiresan | Option | 0 | 30.94 | — |
| Allison Dorval | RSU | 45,000 | — | 253,800 |
| Allison Dorval | Option | 99,015 | 21.76 | — |
equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford Data & Analytics from Aon plc |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-05 | 56,159,136 | 2,748,937 | 478,381 | 95.33% | Passed |
| 2024 | 2024-06-06 | 39,396,050 | 5,481,524 | 25,644 | 87.79% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-06-05 | 95.33%a |
| 2024 | 2024-06-06 | 87.79%b |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast or voted on Proposals No.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast or voted on Proposals No.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jodie MorrisonIndependent · Compensation · Research and Development · Newly elected | $26,971 | $0 | $937,999 | $0 | $0 | $964,970 |
| Ourania Tatsis, Ph.DNot independent · Research and Development (Chair) · Newly elected | 23,118 | 0 | 937,999 | 0 | 0 | 961,117 |
| Burt Adelman, M.DIndependent · Board Chair · Compensation (Chair) · Nominating/Governance (Chair) | 100,000 | 0 | 468,999 | 0 | 0 | 568,999 |
| Michael MacLeanIndependent · Audit (Chair) | 65,000 | 0 | 468,999 | 0 | 0 | 533,999 |
| Sheila Mikhail, J.DIndependent · Audit · Nominating/Governance | 57,500 | 0 | 468,999 | 0 | 0 | 526,499 |
| Krishna Yeshwant, M.DIndependent · Nominating/Governance | 53,668 | 0 | 468,999 | 0 | 0 | 522,667 |
| Lonnel CoatsIndependent · Audit | 52,500 | 0 | 468,999 | 0 | 0 | 521,499 |
| Alexander CumboIndependent · Compensation | 52,500 | 0 | 468,999 | 0 | 0 | 521,499 |
| Sekar Kathiresan, M.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $468,999 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 11,250 / 7,500 / 5,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $431,257 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $431,257 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Verve Therapeutics | 2024 | Sekar Kathiresan | $639,231 | $1,683,000 | $4,727,372 | $378,972 | $7,442,663 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Sekar Kathiresan | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “Summary compensation table” · page 17. As printed: 7,442,663. Filing ↗machine: r2 · c20 · span 327433–327442 |
| 2 | Section 01, Andrew Bellinger | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “Summary compensation table” · page 17. As printed: 3,430,900. Filing ↗machine: r5 · c20 · span 348506–348515 |
| 3 | Section 01, Allison Dorval | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “Summary compensation table” · page 17. As printed: 2,881,705. Filing ↗machine: r11 · c20 · span 388418–388427 |
| 4 | Section 01, Andrew Ashe | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “Summary compensation table” · page 17. As printed: 2,380,065. Filing ↗machine: r8 · c20 · span 369568–369577 |
| 5 | Section 03, Andrew Ashe OPTION | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t9 · r8 · c11 · span 366232–366241 |
| 6 | Section 03, Allison Dorval OPTION | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t9 · r11 · c11 · span 385082–385091 |
| 7 | Section 03, Andrew Ashe PSU | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t9 · r8 · c8 · span 365236–365243 |
| 8 | Section 03, Andrew Bellinger OPTION | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t9 · r5 · c11 · span 345169–345178 |
| 9 | Section 03, Allison Dorval PSU | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t9 · r11 · c8 · span 384086–384093 |
| 10 | Section 03, Andrew Bellinger PSU | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t9 · r5 · c8 · span 344173–344180 |
| 11 | Section 03, Sekar Kathiresan PSU | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t9 · r2 · c8 · span 323099–323108 |
| 12 | Section 03, Sekar Kathiresan OPTION | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t9 · r2 · c11 · span 324097–324106 |
| 13 | Section 08, Jodie Morrison | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “Director Compensation”. As printed: 964,970. Filing ↗machine: t14 · r7 · c11 · span 764491–764498 |
| 14 | Section 08, Ourania Tatsis, Ph.D | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “Director Compensation”. As printed: 961,117. Filing ↗machine: t14 · r8 · c11 · span 768933–768940 |
| 15 | Section 08, Burt Adelman, M.D | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “Director Compensation”. As printed: 568,999. Filing ↗machine: t14 · r2 · c11 · span 742293–742300 |
| 16 | Section 08, Michael MacLean | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “Director Compensation”. As printed: 533,999. Filing ↗machine: t14 · r5 · c11 · span 755607–755614 |
| 17 | Section 08, Sheila Mikhail, J.D | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “Director Compensation”. As printed: 526,499. Filing ↗machine: t14 · r6 · c11 · span 760052–760059 |
| 18 | Section 08, Krishna Yeshwant, M.D | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “Director Compensation”. As printed: 522,667. Filing ↗machine: t14 · r9 · c11 · span 773788–773795 |
| 19 | Section 08, Lonnel Coats | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “Director Compensation”. As printed: 521,499. Filing ↗machine: t14 · r3 · c11 · span 746730–746737 |
| 20 | Section 08, Alexander Cumbo | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “Director Compensation”. As printed: 521,499. Filing ↗machine: t14 · r4 · c11 · span 751170–751177 |
| 21 | Section 08, Sekar Kathiresan, M.D | DEF 14A | 2025-04-25 | 0000950170-25-058325 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 22 | Section 06, 2025 vote | Form 8-K | 2025-06-10 | 0001193125-25-138470 | Item 5.07 · say-on-pay result. As reported: 95.33% (votes for as printed: 56,159,136). Filing ↗ |
| 23 | Section 06, 2024 vote | Form 8-K | 2024-06-07 | 0001193125-24-157327 | Item 5.07 · say-on-pay result. As reported: 87.79% (votes for as printed: 39,396,050). Filing ↗ |
| 24 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 25 | Section 09b board cost (computed) | Computed | — | computed | Cash 431,257 + equity 0 + all other 0 = 431,257, summed across the director compensation table rows.machine: formula: Σ = 431,257 |
| 26 | Verve Therapeutics (subject), Section 10b CEO total | DEF 14A | 2025-04-25 | 0000950170-25-058325 | CEO total compensation as printed in Verve Therapeutics's own proxy. As printed: 7,442,663. Filing ↗machine: r2 · c20 · span 327433–327442 |